Welcome to our dedicated page for Bionexus Gene La news (Ticker: BGLC), a resource for investors and traders seeking the latest updates and insights on Bionexus Gene La stock.
BioNexus Gene Lab Corp. reports developments in precision diagnostics, genomic screening, and its Malaysia-based industrial chemicals subsidiary. The company operates through Chemrex Corporation Sdn. Bhd., which distributes chemical raw materials for industrial applications, and MRNA Scientific Sdn. Bhd., which develops blood-based genomic screening services for disease risk assessment and health management.
Recent company updates center on VitaGuard™, a minimal residual disease liquid biopsy platform for oncology monitoring, including Southeast Asia commercialization rights, regional deployment planning, laboratory and clinical collaborations, and its strategic investment in Fidelion Diagnostics. Other recurring announcements cover subsidiary governance at Chemrex, reporting controls, material agreements, and equity financing arrangements supporting the company’s diagnostics and biotechnology initiatives.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) announces a successful co-investment by the Securities Commission of Malaysia's Malaysia Co-Investment Fund (MyCIF) in Ascension Innovation Sdn Bhd (AISB). This follows BGLC's recent investment in AISB under the Environmental & Social Impact (ESI) Scheme. AISB, a healthcare technology company, is the first to receive investment under the ESI scheme, which supports impactful small and medium enterprises.
The co-investment will accelerate AISB's AI-driven healthcare solutions, particularly its aiCMS platform, designed to enhance clinical management and patient care across Malaysia. This partnership aims to advance the 'One Patient, One Record' initiative under Malaysia's National Electronic Medical Records (EMR) Plan. The total investment in this round amounts to RM1.7 million (approx. USD 390k).
BioNexus Gene Lab Corp. (NASDAQ: BGLC) has completed a strategic RM 1 million (approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a Malaysian healthcare technology firm. The investment, made through BGLC's subsidiary MRNA Scientific Sdn Bhd, gives BGLC a significant equity stake in AISB.
AISB specializes in innovative healthcare technologies, particularly its aiCMS platform, which integrates predictive analytics and AI tools for clinical management. This collaboration aims to combine BGLC's expertise in blood-based genomic screening with AISB's AI-driven platforms to enhance diagnostics and personalized healthcare solutions.
The investment aligns with BGLC's strategy to expand in the growing digital health and AI markets, potentially improving patient outcomes through more accurate diagnostics and tailored treatments.
Summary not available.
Summary not available.
Summary not available.